Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022)

• Published in: Transplantation and cellular therapy 2022-12, Vol.28 (12), p.810-821
• Main Authors: Dioverti, Veronica, Boghdadly, Zeinab El, Shahid, Zainab, Waghmare, Alpana, Abidi, Maheen Z., Pergam, Steven, Boeckh, Michael, Dadwal, Sanjeet, Kamboj, Mini, Seo, Susan, Chemaly, Roy F., Papanicolaou, Genovefa A.
• Format: Article
• Language: English
• Subjects: Adult; Cell- and Tissue-Based Therapy; Cellular therapy; Child; COVID-19; COVID-19 - therapy; Hematopoietic cell transplantation; Hematopoietic Stem Cell Transplantation; Humans; SARS-CoV-2
• ISSN: 2666-6367; 2666-6367
• DOI: 10.1016/j.jtct.2022.09.002

•COVID-19 prevention via vaccination or pre-exposure monoclonal antibodies remain the cornerstone for prevention of severe illness, hospitalization, and death from SARS-CoV-2 in hematopoietic stem cell transplantation and cellular therapy recipients•Optimal timing for transplantation and cellular therapy has to be individualized taking into consideration the urgency of treatment, as well as clinical and other considerations such as severity of illness, therapeutics and circulating variants.•Optimal duration of therapy, sequential therapy or combination therapy have not been studied in HCT/cell therapy recipients. Treatment related mutations are a concern in immunocompromised patients with persistent high-level viral replication.•The long-term outcomes of COVID-19-recovered HCT recipients are yet to be determined. This document is intended as a guide for diagnosis and management of Coronavirus Disease 2019 (COVID-19), caused by the virus SARS-CoV-2, in adult and pediatric HCT and cellular therapy patients. This document was prepared using available data and with expert opinion provided by members of the (ASTCT) Infectious Diseases Special Interest Group (ID-SIG) and is an update of pervious publication. Since our original publication in 2020, the NIH and IDSA have published extensive guidelines for management of COVID-19 which are readily accessible ( NIH Guidelines , IDSA Guidelines ). This update focuses primarily on issues pertaining specifically to HCT/cellular therapy recipients. Information provided in this manuscript may change as new information becomes available.